8-K: Coya Therapeutics Secures $4.2M Milestone for ALS Drug

Coya Therapeutics received a $4.2 million milestone payment from Dr. Reddy's Laboratories following FDA acceptance of its IND for COYA 302 in ALS.

Summary

• Coya Therapeutics, Inc. received a $4.2 million milestone payment from its strategic partner, Dr. Reddy's Laboratories Ltd., on August 29, 2025.
• This payment was triggered by the U.S. Food and Drug Administration's (FDA) acceptance of Coya's Investigational New Drug Application (IND) for COYA 302.
• The IND acceptance allows for the initiation of a planned Phase 2 clinical study to evaluate the safety and efficacy of COYA 302 for the treatment of Amyotrophic Lateral Sclerosis (ALS).
• An additional $4.2 million payment is expected from Dr. Reddy's Laboratories upon the dosing of the first patient in the Phase 2 Study, as per the Development and License Agreement dated December 5, 2023.

Sentiment

Score: 9

Explanation: The filing reports significant positive developments including FDA IND acceptance, a substantial milestone payment, and the clear path to an additional payment and Phase 2 clinical trials for a high-need disease like ALS. This indicates strong progress and validation.

Positives

• Receipt of a $4.2 million milestone payment, enhancing the company's financial liquidity and validating its partnership.
• FDA acceptance of the Investigational New Drug (IND) application for COYA 302, a critical regulatory step enabling progression to Phase 2 clinical trials for ALS.
• Validation of the strategic Development and License Agreement with Dr. Reddy's Laboratories Ltd.
• Anticipation of an additional $4.2 million payment upon the first patient dosing in the Phase 2 study, providing further non-dilutive funding.
• Advancement of a potential therapeutic candidate for Amyotrophic Lateral Sclerosis (ALS), addressing a significant unmet medical need.

Future Outlook

Coya Therapeutics anticipates initiating a Phase 2 clinical study for COYA 302 in ALS and expects to receive an additional $4.2 million payment from Dr. Reddy's Laboratories upon the dosing of the first patient in this study.

Management Comments

• We have received a $4.2 million milestone payment from Dr. Reddy's Laboratories Ltd. due to the FDA's acceptance of our Investigational New Drug Application for COYA 302.
• This IND acceptance allows us to initiate a planned Phase 2 clinical study for COYA 302 for the treatment of Amyotrophic Lateral Sclerosis (ALS).
• An additional $4.2 million payment from Dr. Reddy's Laboratories is anticipated upon the dosing of the first patient in the upcoming Phase 2 study.

Industry Context

The acceptance of an IND by the FDA is a critical step in drug development, allowing a therapeutic candidate to move into human clinical trials. For neurodegenerative diseases like ALS, which currently have limited effective treatments, the progression of new drug candidates like COYA 302 represents a significant development for patients and the broader pharmaceutical industry. Milestone payments from strategic partners like Dr. Reddy's Laboratories are common in biotech, validating the potential of the asset and providing non-dilutive funding for development.

Comparison to Industry Standards

• FDA IND acceptance is a standard and crucial regulatory hurdle for all drug candidates in the U.S., indicating the agency's agreement that the drug is reasonably safe for initial human testing and that the proposed clinical trial design is appropriate.
• Milestone payments, such as the $4.2 million received and the additional $4.2 million expected, are typical components of development and license agreements in the biopharmaceutical industry, reflecting progress through predefined development stages. These payments provide capital to smaller biotech firms like Coya, similar to how companies like Biogen or Novartis might structure deals with emerging biotechs for promising assets.
• Advancing a drug candidate for ALS into Phase 2 trials is a significant achievement, as ALS is a challenging disease with high unmet medical need, comparable to the development efforts seen from companies like Amylyx Pharmaceuticals (with Relyvrio) or Mitsubishi Tanabe Pharma (with Radicava) in the ALS space.

Stakeholder Impact

• Shareholders: Positive impact due to validation of the drug candidate, non-dilutive funding, and progression towards potential market approval, which could increase company value.
• Patients (ALS): Potential for a new treatment option for a severe neurodegenerative disease with high unmet medical need.
• Dr. Reddy's Laboratories Ltd.: Progress in their strategic partnership and investment in COYA 302.
• Employees: Positive impact on morale and job security due to company progress and funding.

Next Steps

• Initiation of the Phase 2 clinical study for COYA 302 for the treatment of ALS.
• Dosing of the first patient in the Phase 2 study, which will trigger an additional $4.2 million payment.

Key Dates

Recommendation

The FDA's IND acceptance for a Phase 2 trial in ALS, coupled with a significant milestone payment and a future payment, represents a major de-risking event and validation of Coya's pipeline. This progress in a high-need therapeutic area, supported by a strategic partner, suggests strong potential for future value creation and warrants a 'strong buy' recommendation for investors looking for growth in the biotech sector.

Keywords

Coya Therapeutics, COYA, Dr. Reddy's Laboratories, DRL, ALS, Amyotrophic Lateral Sclerosis, IND acceptance, Investigational New Drug, Phase 2 study, clinical trial, milestone payment, biotechnology, pharmaceuticals, neurodegenerative disease